Vertex Pharmaceuticals Inc
NASDAQ: VRTX
$477.90
+$3.74 (+0.8%)
Closing Price on September 19, 2024
VRTX Articles
The top analyst upgrades, downgrades and initiations seen on Tuesday morning include AK Steel, Celgene, Darden Restaurants, Delphi Automotive, Johnson & Johnson and U.S. Steel.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Monday morning include Ariad Pharmaceuticals, Comcast, ConEd, Electronic Arts, Kinder Morgan, 3M and Time Warner.
Published:
Last Updated:
In a new research report from Jefferies, many of the outstanding companies in pharmaceuticals and biotech space show up among the stocks to buy.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in late-September and October.
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in September.
Published:
Last Updated:
Credit Suisse has taken a look at which biotech companies in its coverage have the least credit given to pipeline potential at current levels.
Published:
Last Updated:
Sometimes market volatility and outside shocks create a rift between market prices and real value. That may currently be the case in the largest stocks in the biotech sector within health care if...
Published:
Last Updated:
24/7 Wall St. has collected several big FDA decisions and imminent clinical trial results that should be coming up in the June quarter. We have added some color.
Published:
Last Updated:
One portfolio manager on CNBC noted that Vertex could end up being an acquisition target ahead, without mentioning any specifics.
Published:
Last Updated:
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Facebook, First Solar, Hess, Texas Instruments, U.S. Steel, Vertex Pharmaceuticals and Infinera.
Published:
Last Updated:
A new Jefferies research report highlights their top growth picks for this week, and the list is dominated by top biotech stocks.
Published:
Last Updated:
Sometimes after a stock has a good run, the analysts on Wall Street start to get a little gun-shy, especially if they made a good call on the stock and it went up smartly.
Published:
Last Updated:
Despite a modest erosion to fundamentals and sector headwinds, Jefferies does not anticipate any dramatic earnings misses, which could help sentiment continue to turn around.
Published:
Last Updated:
FDA rulings can make or break some companies. 24/7 Wall St. has collected eight key FDA decisions coming up in 2016 or 2017.
Published:
Last Updated:
Jefferies believes most of the significant biotech downside already occurred, though volatility could continue in the near term.
Published:
Last Updated: